Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-27,000
Closed -$6.59M 3456
2024
Q3
$6.59M Sell
27,000
-2,700
-9% -$603K 0.01% 722
2024
Q2
$5.69M Sell
29,700
-6,300
-18% -$1.28M 0.01% 793
2024
Q1
$7.13M Buy
36,000
+28,400
+374% +$5.2M 0.01% 665
2023
Q4
$1.31M Sell
7,600
-1,800
-19% -$277K ﹤0.01% 1965
2023
Q3
$1.39M Buy
+9,400
New +$1.7M ﹤0.01% 1772

Other funds holding RMD

GTS Securities's RMD Position: Q1 2026 in Review

GTS Securities increased its ResMed (RMD) stake by 0.29% in Q1 2026, buying an estimated $997 and bringing the position to 1,385 shares worth $311K. The position accounts for 0.01% of the portfolio, ranked #1066.

GTS Securities first reported a position in RMD in Q4 2023 and has held it in 8 quarters since. The position peaked at $3.84M in Q4 2023. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

  • GTS Securities held 1,385 shares of ResMed worth $311K as of Q1 2026.
  • GTS Securities bought 4 ResMed shares in Q1 2026, an estimated $997.
  • ResMed made up 0.01% of GTS Securities's portfolio in Q1 2026, its #1066 holding.
  • GTS Securities first reported a position in ResMed in Q4 2023 and has held it in 8 quarters since.
  • GTS Securities's ResMed position peaked at $3.84M in Q4 2023.
  • 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.